Ravulizumab Clinical Trials
11 recruitingDrug
Phase 35Phase 22Phase 42
Showing 1–11 of 11 trials
Recruiting
Phase 3
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Kidney TransplantDelayed Graft FunctionDGF
Alexion Pharmaceuticals, Inc.450 enrolled130 locationsNCT06830798
Recruiting
Phase 2
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Preeclampsia
Mayo Clinic14 enrolled1 locationNCT06333652
Recruiting
Phase 4
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
Atypical Hemolytic Uremic SyndromeaHUS
Alexion Pharmaceuticals, Inc.20 enrolled12 locationsNCT07308574
Recruiting
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
Myasthenia Gravis, Generalized
AstraZeneca50 enrolled14 locationsNCT06909253
Recruiting
Phase 3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Phase 4
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
Generalized Myasthenia GravisgMG
Alexion Pharmaceuticals, Inc.75 enrolled12 locationsNCT07221838
Recruiting
Phase 3
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Immunoglobulin A NephropathyIgANIgA Vasculitis+3 more
Alexion Pharmaceuticals, Inc.24 enrolled14 locationsNCT07024563
Recruiting
Phase 3
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
Regeneron Pharmaceuticals190 enrolled69 locationsNCT05133531
Recruiting
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Generalized Myasthenia GravisAnti-AChR Antibody Positive
Alexion Pharmaceuticals, Inc.40 enrolled23 locationsNCT06967480
Recruiting
Phase 2Phase 3
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
Neuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc.12 enrolled21 locationsNCT05346354
Recruiting
Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
Neuromyelitis Optica
University of Texas Southwestern Medical Center35 enrolled1 locationNCT06398158